Evolva business update: Continued good business momentum

• 3Q 2022 revenues more than tripled compared to 3Q 2021
• Year-to-date revenues by end of September already 56% ahead of the same period last year
• Gross contribution margin further increased in 3Q 2022
• On track to reach full-year 2022 targets of CHF 15 million in revenues and a double-digit gross contribution margin

Reinach, 6 October 2022 Evolva (SIX:EVE), a pioneer in the field of natural molecules and industrial biotech, today provides a business update. While July and August are typically months with reduced business activities, Evolva continued to enjoy good business momentum over the last three months. Sales growth amounted to +250% compared to the third quarter of 2021. Year-to-date revenues increased to CHF 11.3 million by the end of September, corresponding to a +56% revenue growth compared to the first 9 months of 2021, and already surpass total FY 2021 revenues by +15%. The gross contribution margin also continued to increase further in 3Q 2022. As such, Evolva is confident to reach the targeted revenue level of CHF 15 million in 2022 (which corresponds to a revenue growth of over 50% compared to 2021) and a double digit gross contribution margin. The cost improvement and cash management measures are ahead of plan and are showing a significant impact.

Christian Wichert, CEO of Evolva, comments: We are happy with the ongoing good business momentum and are actively pursuing multiple initiatives to further accelerate the commercial performance of Evolva.

Important dates

09 March 2023 Full-year 2022 results

18 April 2023  Annual General Meeting
 

Contact

Doris Rudischhauser
Investor Relations and Corporate Communications
+41 79 410 81 88
dorisr@evolva.com
 

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolvas employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at evolva.com and connect with us on LinkedIn.

For Evolva multimedia content, please visit: evolva.com/multimedia-library.

Disclaimer
This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.             
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.